After enjoying a stellar 2014, funds exposed to biotech remain the "easy way out," Finerman said. The SPDR S&P Biotech ETF and iShares Nasdaq Biotechnology ETF, both up more than 25 percent in the last year, moved higher again on Monday.
Read MoreBig deals, data kick off JPMorgan health conference
The First Trust NYSE Arca Biotechnology Index Fund—which holds smaller companies in the sector—hit a 52-week high on Monday.
With stellar fund performance, individual stocks are also poised to do well, traders said. Biotech may have more room to run after some wild upward runs in 2014.
Gilead, for example, hit a snag at the end of last year amid concerns over drug prices. The stock has still gained more than 30 percent in the last year and has settled over $100 per share.
"It's right back where it should be, probably headed higher," said trader Guy Adami.
Read MoreHow to play the JPMorgan health conference
Adami will watch Agios, which is "still pretty interesting," and Celgene, which is "a name forever."
Among other plays were giants Eli Lilly, Johnson & Johnson, Bristol-Myers Squibb and Merck.